Earendil Labs to Present Preclinical Data of HXN-1041, a potential best-in-class IL11 blockade antibody, at Pulmonary Fibrosis Foundation Summit 2025 (PFF Summit 2025)

MIDDLETOWN, Del., – October 31, 2025 – Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced that preclinical data for HXN-1041, biparatopic IL11 blockade antibody, will be presented in poster at the Pulmonary Fibrosis Foundation Summit 2025 (PFF Summit 2025) in Chicago, Illinois from November 13-15, 2025.

The abstract details are below:

Abstract Title: "Development of a biparatopic IL11 blockade antibody for fibrotic diseases"

Format: Poster Presentation

Date and Time: Thursday, November 13 from 5:00 p.m.–8:00 p.m.

HXN-1041 is an innovative biparatopic antibody that binds two distinct epitopes of IL11, offering exceptional inhibitory potency and druggability. Earendil Labs (Helixon therapeutics) is developing HXN-1041 as part of its broad and innovative pipeline. It holds significant potential for the treatment of fibrotic diseases, cancer and aging.

About Earendil Labs, Earendil Labs is a US-based biotech company redefining biopharmaceutical innovation with its cutting-edge AI-powered platform. By combining advanced machine learning, generative protein engineering, and high-throughput experimental techniques, Earendil Labs and its affiliate Helixon Therapeutics streamline drug discovery & research process with aim of significantly accelerating drug development. Earendil Labs' proprietary integrated framework enables precise optimization of functionality, manufacturability, and developability of protein-based biologics with first-in-class or best-in-class potential.

About HXN-1041

HXN-1041, a biparatopic anti-IL11 antibody, is engineered based on two building blocks, which can simultaneously target the IL11:IL11Rα interface and the IL11: gp130 binding site. HXN-1041 effectively inhibits both classic and trans IL11 signaling pathways, with superior potency to clinical-stage benchmarks. HXN-1041 significantly inhibits TNFβ-induced fibroblast activation, and showed superior anti-fibrosis efficacy in bleomycin-induced mouse models.